Targeting urologists and oncologists - for focus groups to be held after 31 July 2026 Do you support patients with low or intermediate-risk prostate cancer? Researchers from the University of Southampton are inviting urologists and oncologists to help refine an...
A Joint British Association of Day Surgery & HCUK Virtual Conference Urology is a specialty that is especially attuned to day surgery procedures. Variation is still present Nationally and barriers exist to achieving higher daycase rates and excellence in day...
Welcome from the Honorary Secretary I am thrilled to extend a warm welcome to each and every one of you as we gear up for what promises to be an enriching and enlightening conference experience. On behalf of Mo Belal,...
This article is the second in a three-part series which follows directly on from the first part which concentrated on the rationale for going on a fellowship, as well as some of the administrative hurdles you might face in planning...
With the ongoing shortage of BCG remaining an issue for urologists in the UK and further afield, this topical paper presented the results of the CUETO study evaluating the outcome of a modified three-year BCG maintenance regimen versus induction therapy...
The role of androgens in the pathogenesis of prostate cancer is quite complex and is not entirely clear yet. Despite several reports suggesting testosterone use is safe in patients diagnosed with prostate cancer, many clinicians are still reluctant to use...
The standard practice for testicular masses confirmed on ultrasound has been to offer an inguinal orchidectomy, on the presumption that the mass represents testicular cancer. The growing use of scrotal ultrasound for various indications has led to an increase in...
Micropos Medical is a Swedish company developing technology for enhanced radiotherapy cancer treatment. Their Raypilot® System offers accuracy through real-time tumor tracking in prostate cancer radiation treatment. The 2024 Pace-B study showed that SBRT with five sessions is as effective...
Mirabegron is a beta-3 agonist used in the treatment of overactive bladder (OAB). Trials have shown reduced side-effects but equal efficacy when compared to anticholinergics. The authors wished to examine patients’ persistence with treatment, in a non-trial setting, over a...
The risk of a women developing a urinary tract infection in her lifetime is over 50%, approximately 25% of which become recurrent (rUTIs). This study examined the viewpoints of women with rUTIs through six focus groups at a tertiary centre...
An estimated 3-5 million adults in UK have urinary incontinence and the NHS spends an estimated £80 million a year on Incontinence pads (NHS England, 2018). Often people who have urinary incontinence receive poor quality care that does not meet...
Bladder augmentation is utilised to treat children with neuropathic bladders secondary to spina bifida that results in hostile urodynamics, renal deterioration and / or urinary incontinence. Whilst it is associated with an improved quality of life and low mortality, it...